Patent Claims

1. Process for the production of an orally administrable multiple-unit sustained-release dose formulation having controlled agitation-independent release, characterized in that the hydrophilic polymer HPC having an average molecular weight of 250 000 to 1 200 000 is combined in an amount from 40 to 95% by weight, based on the active compound-polymer mixture and a molar degree of substitution of at least 3, as a release-sustaining erosion material, with at least one pharmaceutical active compound and this active compound-polymer combination is converted into small particles having a diameter of 0.2 to 3.0 mm and these are used in the production of active oral administration forms and finished medicaments.

2. Process for the production of a formulation according to Claim 1, characterized in that HPC is employed in an amount from 45 to 90% by weight.

3. Process for the production of a formulation according to Claim 1, characterized in that HPC having an average molecular weight of 350 000 to 1 150 000 is employed.

4. Process for the production of a formulation according to Claim 1, characterized in that the active compound-polymer combination is converted into small particles having a maximum diameter of 0.5 to 2 mm.

5. Process for the production of formulations according to Claim 1, characterized in that the particles for the active compound-polymer combination are produced by melt extrusion and granulation.

6. Process for the production of formulations according to Claim 1, characterized in that the particles of the active compound-polymer combination are produced by conventional tableting methods.

7. Process for the production of formulations according to Claim 1, characterized in that the active compound-polymer combination particles are produced in the form of pellets, granules, minitablets or grains and these are filled into capsules in an efficacious dosage.

8. Process for the production of formulations according to Claim 1, characterized in that the active compound-polymer combination particles are additionally lacquered.

9. Use of HPC having an average molecular weight of 250 000 to 1 200 000 in the production of agitation-independent pharmaceutical sustained-release preparations, obtainable according to Claim 1.

10. Use of HPC having an average molecular weight of 350 000 to 1 150 000 as main sustained-release polymer and, if appropriate, small amounts of further hydrophilic polymers such as polymethacrylic esters in the production of agitation-independent sustained-release preparations according to Claim 1.

11. Use of active compound-polymer combination particles according to Claim 1 for the production of finished medicaments in the form of capsules or tablets.

12. Orally administrable multiple-unit sustained-release dose formulations having controlled agitation-independent release obtainable according to Claim 1.